Comprehensive Review on Alzheimer's Disease and Tau Modifications
Author Information
Author(s): Xin Li, Zhisheng Ba, Juan Huang, Jianhua Chen, Jinyu Jiang, Nanqu Huang, Yong Luo
Primary Institution: The Third Affiliated Hospital of Zunyi Medical University
Hypothesis
The review explores the role of posttranslational modifications of Tau in Alzheimer's disease and their potential as therapeutic targets.
Conclusion
Targeting specific posttranslational modifications of Tau may lead to novel therapeutic strategies for Alzheimer's disease.
Supporting Evidence
- Tau aggregation is more closely associated with cognitive decline than Aβ in Alzheimer's disease.
- Different types of posttranslational modifications have varying impacts on Tau's structure and function.
- Current research is more extensive on phosphorylation, acetylation, ubiquitination, and methylation.
- Drug development targeting Tau modifications is still in the early stages.
Takeaway
This study looks at how changes to a protein called Tau can cause problems in the brain for people with Alzheimer's, and suggests new ways to help treat it.
Methodology
The review summarizes existing research on the posttranslational modifications of Tau and their implications for drug development.
Limitations
The review highlights that most research is still in the basic research stage and clinical studies on PTM-regulated Tau are scarce.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website